Novo Nordisk A/S (NVO) Revenue CAGR:17.42%(TTM)
Revenue CAGR uses precomputed financial statement history.
Over longer horizons, Novo Nordisk A/S's Revenue CAGR averages 24.65% over 3 years and 20.73% over 5 years.The TTM figure compares the trailing 12 months (sum of the latest four quarters) with the 12 months before that. Rows in the history table compare fiscal years, and the quarterly table compares single quarters; the three measure different windows and will differ. Revenue CAGR measures how Novo Nordisk A/S's top-line revenue has grown over time. Consistent revenue growth is a key indicator of business expansion and market share gains.
NVO Revenue CAGR Chart
Novo Nordisk A/S (NVO)
NVO Quarterly Revenue Growth (YoY)
Revenue growth vs the same quarter one year earlier, last 20 quarters.
NVO Revenue CAGR History
| Year | Start Revenue | End Revenue | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2025 | $40.19B | $48.49B | +$8.30B | +20.65% | +20.65% |
| 2024 | $34.38B | $40.19B | +$5.81B | +16.91% | +16.91% |
| 2023 | $25.39B | $34.38B | +$8.99B | +35.39% | +35.39% |
| 2022 | $21.52B | $25.39B | +$3.87B | +18.00% | +18.00% |
| 2021 | $20.79B | $21.52B | +$726.12M | +3.49% | +3.49% |
| 2020 | $18.27B | $20.79B | +$2.53B | +13.84% | +13.84% |
| 2019 | $17.18B | $18.27B | +$1.09B | +6.34% | +6.34% |
| 2018 | $17.97B | $17.18B | $-794.64M | -4.42% | -4.42% |
| 2017 | $15.81B | $17.97B | +$2.17B | +13.71% | +13.71% |
| 2016 | $15.70B | $15.81B | +$102.31M | +0.65% | +0.65% |
| 2015 | $14.42B | $15.70B | +$1.28B | +8.88% | +8.88% |
| 2014 | $15.39B | $14.42B | $-971.87M | -6.31% | -6.31% |
| 2013 | $13.76B | $15.39B | +$1.64B | +11.91% | +11.91% |
| 2012 | $11.54B | $13.76B | +$2.22B | +19.23% | +19.23% |
| 2011 | $10.88B | $11.54B | +$658.67M | +6.05% | +6.05% |
| 2010 | $9.81B | $10.88B | +$1.07B | +10.93% | +10.93% |
| 2009 | $8.54B | $9.81B | +$1.26B | +14.78% | +14.78% |
| 2008 | $8.17B | $8.54B | +$371.63M | +4.55% | +4.55% |
| 2007 | $6.84B | $8.17B | +$1.33B | +19.42% | +19.42% |
| 2006 | $5.35B | $6.84B | +$1.49B | +27.87% | +27.87% |
| 2005 | $5.32B | $5.35B | +$30.37M | +0.57% | +0.57% |
| 2004 | $4.50B | $5.32B | +$820.61M | +18.23% | +18.23% |
| 2003 | $4.04B | $4.50B | +$456.54M | +11.29% | +11.29% |
| 2002 | $3.81B | $4.04B | +$231.07M | +6.06% | +6.06% |
| 2001 | $3.35B | $3.81B | +$466.62M | +13.94% | +13.94% |
| 2000 | $2.64B | $3.35B | +$703.13M | +26.60% | +26.60% |
| 1999 | $2.19B | $2.64B | +$449.13M | +20.47% | +20.47% |
| 1998 | $2.73B | $2.19B | $-536.27M | -19.64% | -19.64% |
| 1997 | $2.40B | $2.73B | +$334.46M | +13.96% | +13.96% |
Quarterly Revenue: QoQ & YoY
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Q1 2026 | $14.93B | +20.2% | +32.0% |
| Q4 2025 | $12.42B | +5.6% | +4.7% |
| Q3 2025 | $11.76B | -2.9% | +10.5% |
| Q2 2025 | $12.11B | +7.0% | +23.5% |
| Q1 2025 | $11.31B | -4.6% | +20.0% |
| Q4 2024 | $11.86B | +11.4% | +21.6% |
| Q3 2024 | $10.64B | +8.6% | +28.1% |
| Q2 2024 | $9.80B | +3.9% | +23.5% |
| Q1 2024 | $9.43B | -3.3% | +21.7% |
| Q4 2023 | $9.75B | +17.4% | +41.3% |
| Q3 2023 | $8.30B | +4.7% | +38.7% |
| Q2 2023 | $7.93B | +2.4% | +36.8% |
| Q1 2023 | $7.75B | +12.3% | +23.9% |
| Q4 2022 | $6.90B | +15.3% | +17.8% |
| Q3 2022 | $5.99B | +3.3% | +7.9% |
| Q2 2022 | $5.80B | -7.3% | +10.1% |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
About Novo Nordisk A/S
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging therapeutic areas. Meanwhile, the Rare Disease division concentrates on providing treatments for rare blood disorders, uncommon endocrine conditions, and hormone replacement solutions. In addition to its core pharmaceutical offerings, Novo Nordisk produces specialized medical equipment such as insulin pens, growth hormone pens, and injection needles. It also pioneers smart digital solutions for diabetes management, including advanced insulin pens and the Dose Check application, designed to guide insulin dosage. The company engages in strategic alliances, notably a partnership with UNICEF to combat childhood obesity and a collaboration with Valo Health, Inc. to discover and advance novel drug pipelines in the cardiometabolic space. Founded in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Maziar Mike Doustdar